Pipeline Strategy and Progress
Globally competitive Pipeline Globally competitive Pipeline

With a strategic emphasis on oncology, we have built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development, including small molecules, monoclonal/bifunctional antibodies and oncolytic virus.


Currently, we have three programs that are being investigated in clinical trials:

  • An FDA Fast Track-designated treatment AN2025 (Buparlisib) for head and neck squamous cell carcinoma (HNSCC) in a global phase III clinical trial;

  • FDA Fast Track-designated intravenously-administered oncolytic virus AN1004 (Pelareorep) to have completed a phase II clinical trial;

  • An oral EP4 antagonist AN0025 (Palupiprant) is in early-stage clinical development in multiple tumor types in combination with other treatment options including chemo-radiation and anti‑PD‑(L)1 therapies.


We have also accumulated a number of preclinical drug candidates, including AN4005 (an oral PD-L1 inhibitor), AN6025 (HPK1 inhibitor) and AN3025 (TNFR2).


We are working on discovering combination solutions while developing unique 'cocktail therapy', aiming to bring effective treatment for patients.


Pre-clinical
Phase Ia
Phase Ib
Phase II
Phase III
NDA
AN2025
Buparlisib
HNSCC
Global
PIK3CA
mutation
Global
AN0025
Palupiprant
Multiple solid
tumors
(+Keytruda)
Global (Excluding Japan, South Korea, and partial Southeast Asia Counties)
Neo-adjuvant
rectum cancer
(+RT/CRT)
Global (Excluding Japan, South Korea, and partial Southeast Asia Counties)
AN1004
Pelareorep
HR+/HER2-mbc
(+Paclitaxel)
Great China Region, Singapore, South Korea
AN4005
PD-L1
Solid tumors
Global
AN6025
HPK1
Solid tumors
Global
AN3025
TNFR2
Solid tumors
Global